Professional Documents
Culture Documents
CHAPTER 17
PREOPERATIVE EVALUATION
James C. Duke, MD, MBA, and Mark Chandler, MD
Major cardiac events include myocardial infarction, pulmonary edema, ventricular fibrillation, primary cardiac arrest, and complete
heart block.
KEY PO I N T S : P R E O P E R A T I V E E V A L U A T I O N
1. Preoperative laboratory testing should be selective and individualized.
2. Current ACC/AHA guidelines for cardiac testing prior to noncardiac procedures are the gold
standard for preoperative cardiac risk assessment.
3. The most important preanesthetic evaluation includes a thorough, accurate, and focused history
and physical examination.
4. A patient’s baseline hemoglobin tends to predict the need for transfusion when large blood loss
occurs.
5. The four active cardiac conditions that will likely result in surgical cancellation to assess cardiac
evaluation and treatment are unstable coronary syndrome, decompensated heart failure,
significant cardiac arrhythmias, and severe valvular disease.
6. Before halting a patient’s anticoagulation, one must consider the type and urgency of surgery, the
possibility and consequences of intraoperative hemorrhage, and the reason why the patient is
anticoagulated
12. What benefits and risks are associated with preoperative cigarette cessation?
How long before surgery must a patient quit smoking to realize any health
benefits?
Patients randomized to receive an intervention to help them stop smoking 6 to 8 weeks
before surgery saw a dramatic decrease in the overall complication rate in the smoking
cessation group, mainly from diminished wound infections. The longer a patient can
abstain from smoking before surgery, the greater the perioperative health benefit will be:
bronchociliary function improves within 2 to 3 days of cessation, and sputum volume
decreases to normal levels within about 2 weeks.
13. For patients scheduled for noncardiac surgery, what are guidelines for
perioperative cardiac evaluation?
An algorithmic approach to perioperative cardiac evaluation in patients who will undergo
noncardiac surgery requires assessment of a patient’s cardiac risks before surgery, taking into
account the urgency of surgery, the presence of active cardiac conditions, the invasiveness of
the planned surgery, the patient’s functional status, and the presence of clinical risk factors
for ischemic heart disease. Taken together, this algorithm underscores the importance of a
history focused on cardiac issues for all surgical patients.
14. What are the clinical risk factors for a major perioperative cardiac event?
The Revised Cardiac Risk Index (see Box 17-1) has six components: surgical risk, history of
ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease,
preoperative treatment with insulin, and elevated preoperative serum creatinine. The
patient is assigned one point for each of these risk factors, which are then translated into
percentage risks of perioperative major cardiac events such as myocardial infarction,
pulmonary edema, ventricular fibrillation, primary cardiac arrest, and complete heart block.
15. What constitutes the basic laboratory evaluation of coagulation status?
The basic laboratory evaluation includes platelet count, prothrombin time (PT), partial
thromboplastin time (PTT), and thrombin time. Thromboelastography is growing as a
methodology. Thromboelastography measures the combined function of platelets and
coagulation factors. The minimal number of normally functioning platelets to prevent
surgical bleeding is 50,000/mm3. Both the PT and PTT require about a 60% to 80% loss of
coagulation activity before becoming abnormal, but patients with smaller decreases in
function can still have significant surgical bleeding. Therefore the history is still very
important.
16. Are there special anesthetic considerations for surgical patients on warfarin?
Warfarin is a vitamin K antagonist and is used to prevent thrombosis and emboli. A patient
on warfarin is at high risk for intraoperative bleeding. Before stopping a patient’s warfarin,
it is important to know the indication for anticoagulation, the type and urgency of the
surgery, and the consequences of intraoperative bleeding. Patients who are at very high risk
of thromboembolism but nonetheless need to discontinue their anticoagulant (e.g.,
warfarin) in the perioperative setting are often bridged with low-molecular-weight heparin,
another much shorter-acting anticoagulant. Because warfarin has such a long half-life
(about 2.5 days) and heparin has such a short half-life (about 1.5 hours), a patient may be
instructed to stop warfarin 4 days before surgery and then, often as an inpatient, undergo
regular heparin injections up until a few hours before surgery. Once the surgery is completed
(and depending on the postoperative bleeding risk), the warfarin can be restarted.
17. What are considerations for patients with coronary stents?
Coronary stents, small metal mesh tubes that maintain patency of stenosed coronary
arteries, fall into two broad categories: bare metal stents and drug-eluting stents. The latter
slowly release a chemical that helps prevent endothelialization. An ongoing debate among
cardiologists is how long after stent placement a patient should remain anticoagulated. This
anticoagulation issue adds considerably to the complexity of recommending cardiac workups
for patients undergoing surgery. Patients with recent stent placement should not undergo
surgery right away because delays in anticoagulants are known to precipitate acute
myocardial infarctions.
18. Why is it necessary to evaluate patients for obstructive sleep apnea (OSA)
before surgery, and how should OSA be identified?
Patients with OSA are known to have increased postoperative morbidity. Identifying those
at risk remains a challenge despite an OSA diagnosis. Several screening tools (e.g.,
STOP-Bang, Berlin, and Flemons questionnaires) continue to challenge anesthesiologists
regarding appropriate postoperative disposition.
SUGGESTED READINGS
Practice Advisory for Preanesthesia Evaluation: An Updated Report by the American Society of
Anesthesiologists Task Force on Preanesthesia Evaluation, Anesthesiology 116(3):522–538, 2012.
Chung F, Yegneswaran B, Liao P, et al: Validation of the Berlin questionnaire and American Society of
Anesthesiologists checklist as screening tools for OSA in surgical patients, Anesthesiology 108:822–830,
2008.
Eagle KA, Berger PB, Calkins H, et al: ACC/AHA Guideline update for perioperative cardiac evaluation for
noncardiac surgery, Anesth Analg 94:1052–1064, 2002.
Gall B, Whalen FX, Schroder DR, et al: Identification of patients at risk for postoperative respiratory
complications using a preoperative OSA screening tool and post-anesthesia care assessment,
Anesthesiology 110:869–877, 2009.
Møller AM, Villebro N, Pedersen T, et al: 2002 Effect of preoperative smoking intervention on postoperative
complications: a randomised clinical trial, Lancet 359:114–117, 2002.
Sweitzer BJ: Preoperative evaluation and medication. In Miller RD, Pardo MC, editors: Basics of anesthesia,
ed 6, Philadelphia, 2011, Elsevier Saunders, pp 165–188.
Wijeysundera DM, Austin PC, Beattie WS, et al: Less is more. Outcomes and processes of care relate to
preoperative consultation, Arch Intern Med 170:1365–1374, 2010.